Please login to the form below

Eklira

This page shows the latest Eklira news and features for those working in and with pharma, biotech and healthcare.

AZ adds to respiratory portfolio with Actavis drugs

It follows a similar deal agreed in July last year for AZ to buy the global respiratory portfolio of Almirall for $2bn, including the approved Eklira (aclidinium) for COPD and several

Latest news

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

Almirall's franchise includes Eklira (aclidinium), LAS40464 (a combination of aclidinium with formoterol, which has been filed in Europe), LAS100977 (abediterol), a once-daily phase II long-acting beta2-agonist (LABA),
Almirall expands in US via $400m deal to buy Aqua

under 22m on the back of high roll-out costs for new products such as Sativex (nabiximols) for spasticity in multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD) treatment Eklira
IQWiG knocks back Almirall's Eklira

IQWiG knocks back Almirall's Eklira. Decides added benefit of COPD drug is not proven. ... A long-acting bronchodilator, Eklira is licensed to treat adults with chronic-obstructive pulmonary disease (COPD) and works by widening their narrowed airways.
Forest Labs launches COPD drug Tudorza in US

sold as Eklira and Bretaris Genuair.
Almirall's IBS drug Constella backed by CHMP

COPD) treatment Eklira/Tudorza (aclidinium bromide).

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

Deal Watch table for November 2014

Eklira and Duaklir. Business unit acquisition. 3, 075. Pfizer / Merck KGaA.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Scientific Director: Great salary and bebefits

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Programme Executive: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer: Great salary and benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editorial Director – Medical Education – Oxford: Negotiable

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager / Account Director: Great salary and bebefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...